• 2022-09
  • 2022-08
  • 2022-07
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2018-07
  • br AS HJM agreed to be


    • AS, HJM, agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
    [6] Gil-Rendo A, Martínez-Regueira F, Zornoza G, García-Velloso MJ, Beorlegui C, and Rodriguez-Spiteri N (2009). Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg 96(2), 166–170.
    [7] Sasaki M, Tozaki M, Kubota K, Murakami W, Yotsumoto D, Sagara Y, Ohi Y, Oosako S, and Sagara Y (2018). Simultaneous whole-body and breast 18F-FDG PET/MRI examinations in patients with breast cancer: a comparison of apparent 11078-21-0 coefficients and maximum standardized uptake values. Jpn J Radiol 36 (2), 122–133.
    [8] Ahn SG, Park JT, Lee HM, Lee HW, Jeon TJ, Han K, Lee SA, Dong SM, Ryu YH, and Son EJ, et al (2014). Standardized uptake value of 18F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden. Breast Cancer Res 16, 502. [9] Higuchi T, Nishimukai A, Ozawa H, Fujimoto Y, Yanai A, Miyagawa Y, Murase K, Imamura M, Takatsuka Y, and Kitajima K, et al (2016). Prognostic significance of preoperative 18F-FDG PET/CT for breast cancer subtypes. Breast 30, 5–12.
    [10] Wang J, Shih TT, and Yen RF (2017). Multiparametric Evaluation of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer Using Integrated PET/MR. Clin Nucl Med 42(7), 506–513.
    [11] Ohara M, Shigematsu H, Tsutani Y, Emi A, Masumoto N, Ozaki S, and Kadoya T (2013). Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer: usefulness for malignant grade of triple-negative breast cancer. Breast 22, 958–963.
    [12] Kadoya T, Aogi K, Kiyoto S, Masumoto N, Sugawara Y, and Okada M (2013). Role of maximum standardized uptake value in fluorodeoxyglucose positron emission tomography/computed tomography predicts malignancy grade and prognosis of operable breast cancer: a multi-institute study. Breast Cancer Res Treat 141(269)e75.
    [13] Heudel P, Cimarelli S, Montella A, Bouteille C, and Mognetti T (2010). Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. Int J Clin Oncol 15(6), 588–593.
    [15] Avril N, Menzel M, Dose J, Schelling M, Weber W, Jänicke F, Nathrath W, and Schwaiger M (2001). Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 42(1), 9–16.
    [16] Bitencourt AG, Lima EN, Chojniak R, Marques EF, de Souza JA, Graziano L, Andrade WP, and Osório CA (2014). Correlation between PET/CT results and histological and immunohistochemical findings in breast carcinomas. Radiol Bras 47(2), 67–73.
    [20] Cochet A, Pigeonnat S, Khoury B, Vrigneaud JM, Touzery C, Berriolo-Riedinger A, Dygai-Cochet I, Toubeau M, Humbert O, and Coudert B, et al (2012). Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: comparison with angiogenesis markers and prognostic factors. J Nucl Med 53(4), 512–520.
    [21] Contractor KB, Kenny LM, Stebbing J, Challapalli A, Al-Nahhas A, Palmieri C,
    Shousha S, Lewis JS, Hogben K, and De Nguyen Q, et al (2011). Biological basis of [11C]choline-positron emission tomography in patients with breast cancer: comparison with [18F]fluorothymidine positron emission tomography. Nucl Med Commun 32(11), 997–1004.
    [22] Crippa F, Agresti R, Sandri M, Mariani G, Padovano B, Alessi A, Bianchi G, Bombardieri E, Maugeri I, and Rampa M, et al (2015). 18F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study.
    [23] de Cremoux P, Biard L, Poirot B, Bertheau P, Teixeira L, Lehmann-Che J, Bouhidel FA, Merlet P, Espié M, and Resche-Rigon M, et al (2018). 18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemother-apy and outcome in HER2-negative advanced luminal breast cancers patients. Oncotarget 9(23), 16343–16353.
    [24] Ege Aktas G, Taştekin E, and Sarikaya A (2018). Assessment of biological and clinical aggressiveness of invasive ductal breast cancer using baseline 18F-FDG PET/CT-derived volumetric parameters. Nucl Med Commun 39(1), 83–93.
    [25] García García-Esquinas M, García-Sáenz JA, Arrazola García J, Enrique Fuentes Ferrer M, Furió V, Rodriguez Rey C, Román JM, and Carreras Delgado JL (2014). 18F-FDG PET-CT imaging in the neoadjuvant setting for stages II-III breast cancer: association of loco regional SUVmax with classical prognostic factors. Q J Nucl Med Mol Imaging 58(1), 66–73.